kabutan

OncoTherapy Science, Inc.(4564) Summary

4564
TSE Growth
OncoTherapy Science, Inc.
22
JPY
-1
(-4.35%)
Mar 13, 3:30 pm JST
0.13
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
21.7
Mar 13, 11:57 pm JST
Summary Chart Historical News Financial Result
PER
PBR
4.01
Yield
ー%
Margin Trading Ratio
4.45
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
22 JPY 0.13 USD
Previous Close Mar 12
23 JPY 0.14 USD
High Mar 13, 9:01 am
23 JPY 0.14 USD
Low Mar 13, 12:48 pm
21 JPY 0.13 USD
Volume
76,351,400
Trading Value
1.69B JPY 0.01B USD
VWAP
22.13 JPY 0.14 USD
Minimum Trading Value
2,200 JPY 13 USD
Market Cap
8.29B JPY 0.05B USD
Number of Trades
108
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
Mid
1-Year Average
233
1-Year High Jun 30, 2025
2,195
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 1,305,900 20,709,600 15.86
Feb 27, 2026 655,500 19,888,800 30.34
Feb 20, 2026 1,185,600 21,301,700 17.97
Feb 13, 2026 925,900 22,032,400 23.80
Feb 6, 2026 581,200 22,066,000 37.97
Company Profile
OncoTherapy Science, Inc. is a drug discovery venture originating from the Institute of Medical Science at the University of Tokyo. The company's main focus is on cancer gene analysis and the development of cancer therapeutics.
Sector
Pharmaceuticals
OncoTherapy Science, Inc. is a research and development-oriented venture that broadly engages in cancer drug development, from drug discovery research to clinical trials. The company promotes R&D in various areas including small molecule drugs, cancer peptide vaccines, and antibody drugs, with multiple ongoing clinical trials. Through its subsidiary, OncoTherapy Science also conducts large-scale cancer gene analysis tests and research and development of cancer immunotherapy, thus engaging in cancer precision medicine-related businesses. The company aims to realize personalized medicine through these efforts. OncoTherapy Science has established a staged revenue model including upfront payments, milestones, and royalties through partnerships with major pharmaceutical companies. The company is characterized by its long-term approach to research and development. As a result, its financial performance largely depends on the development progress of partnering pharmaceutical companies and the sales status of pharmaceuticals, which may not be reflected in short-term results in many cases.